Results 1 to 10 of about 152,029 (233)

A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults

Human Vaccines & Immunotherapeutics, 2021
Respiratory Syncytial Virus (RSV) causes lower respiratory tract infections that can be severe and sometimes fatal. The risk for severe RSV infection is highest in infants and older adults.
Antonios O. Aliprantis, Christine A. Shaw, Paul Griffin, Nicholas Farinola, Radha A. Railkar, Xin Cao, Wen Liu, Jeffrey R. Sachs, Christine J. Swenson, Heather Lee, Kara S. Cox, Daniel S. Spellman, Colleen J. Winstead, Igor Smolenov, Eseng Lai, Tal Zaks, Amy S. Espeseth, Lori Panther   +17 more
doaj   +2 more sources

The incidence and clinical burden of respiratory syncytial virus disease identified through hospital outpatient presentations in Kenyan children [PDF]

, 2012
There is little information that describe the burden of respiratory syncytial virus (RSV) associated disease in the tropical African outpatient setting. Methods We studied a systematic sample of children aged
Ann Bett, Benjamin J. Cowling, BG Williams, BJ Selwyn, CB Hall, D. James Nokes, DJ Nokes, DJ Nokes, DJ Nokes, EA Okiro, EA Okiro, EA Okiro, Emelda A. Okiro, F Freymuth, F Henderson, FE Moura, I Rudan, J Bryce, JAG Scott, K Mulholland, MK Mwaniki, MP Loscertales, MP Loscertales, MW Weber, MW Weber, MW Weber, Mwanajuma Ngama, PD Scott, PD Scott, PD Scott, R Ochola, RG Fisher, SA Madhi, SE Robertson, TW Mwangi, W Glezen   +35 more
core   +23 more sources

Co-Infection Rates between SARS-CoV-2 and RSV in Oropharyngeal, Nasopharyngeal Aspirate and Saliva Samples of COVID-19 Patients, Shiraz, South of Iran [PDF]

Journal of Dentistry, 2023
Statement of the Problem: Determining the prevalence of respiratory viruses' coinfection with coronavirus disease 2019 (COVID-19) is essential to defining its true clinical influence.Purpose: This study aimed to evaluate co-infection rates between severe
Jannan Ghapanchi, Ali Dehghani Nazhvani, Fahimeh Rezazadeh, MItra Farzin, Afagh Moatari, Sina Masoudi, Mohamad Reza Kalantari, Reza Derafshi, Hossein Sedarat   +8 more
doaj   +1 more source

Effects of COVID-19 Infection Control Strategies on Seasonal Influenza Virus Epidemiology and Evolution [PDF]

Journal of Health Sciences and Surveillance System, 2023
This article has no abstract.
Amir Emami
doaj   +1 more source

Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.

New England Journal of Medicine, 2023
BACKGROUND Whether vaccination during pregnancy could reduce the burden of respiratory syncytial virus (RSV)-associated lower respiratory tract illness in newborns and infants is uncertain.
B. Kampmann, S. Madhi, I. Munjal, E. Simões, B. Pahud, C. Llapur, J. Baker, Gonzalo Pérez Marc, D. Radley, Emma Shittu, Julia R Glanternik, Hasra K Snaggs, James Baber, Philip Zachariah, S. Barnabas, Merlin Fausett, Tyler Adam, Nicole Perreras, M. V. van Houten, A. Kantele, Li-Min Huang, L. Bont, Takeo Otsuki, Sergio L Vargas, Joanna Gullam, B. Tapiéro, R. Stein, F. Polack, H. Zar, N. B. Staerke, María Duron Padilla, Peter C. Richmond, K. Koury, Katherine Schneider, E. V. Kalinina, David Cooper, K. Jansen, A. Anderson, K. Swanson, W. Gruber, A. Gurtman   +40 more
semanticscholar   +1 more source

El humor en la crónica deportiva: Recursos humorísticos de Andrés Montes en las narraciones de la NBA

Estudios de Lingüística del Español, 2021
El humor es un fenómeno interdisciplinar a la vez que polifuncional. Como género, ha dado lugar a distintos formatos (chiste, monólogo, parodia, sketch…), pero es, además, un poderoso recurso del que se sirven otros géneros no propiamente humorísticos ...
Mar Galindo Merino, Ángel López Fernández   +1 more
doaj   +1 more source

Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults.

New England Journal of Medicine, 2023
BACKGROUND Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality among older adults. An mRNA-based RSV vaccine, mRNA-1345, encoding the stabilized RSV prefusion F glycoprotein, is under clinical investigation.
Eleanor Wilson, Jaya Goswami, A. Baqui, P. A. Doreski, Gonzalo Perez-Marc, Khalequ Zaman, Jorge Monroy, Christopher J A Duncan, Mugen Ujiie, Mika Rämet, Lina Pérez-Breva, A. Falsey, Edward E. Walsh, Rakesh Dhar, Lauren Wilson, Jiejun Du, Parinaz Ghaswalla, Archana Kapoor, Lan Lan, Shraddha Mehta, Runa Mithani, C. A. Panozzo, Alana K Simorellis, B. Kuter, Florian Schödel, Wenmei Huang, Caroline Reuter, Karen Slobod, S. Stoszek, Christine A. Shaw, Jacqueline Miller, R. Das, Grace L Chen   +32 more
semanticscholar   +1 more source

Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.

New England Journal of Medicine, 2023
BACKGROUND The safety of the monoclonal antibody nirsevimab and the effect of nirsevimab on hospitalizations for respiratory syncytial virus (RSV)-associated lower respiratory tract infection when administered in healthy infants are unclear. METHODS In
S. Drysdale, Katrina Cathie, F. Flamein, M. Knuf, Andrea M Collins, Helen C Hill, Friedrich Kaiser, Robert Cohen, Didier Pinquier, C. Felter, N. C. Vassilouthis, Jing Jin, Mathieu Bangert, K. Mari, R. Nteene, Sophie Wague, M. Roberts, P. Tissières, S. Royal, S. Faust   +19 more
semanticscholar   +1 more source

Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.

New England Journal of Medicine, 2022
BACKGROUND Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion protein that has an extended half-life.
L. Hammitt, R. Dagan, Yuan Yuan, M. Baca Cots, M. Bosheva, S. Madhi, W. Muller, H. Zar, Dennis Brooks, Amy Grenham, U. Wählby Hamrén, V. S. Mankad, P. Ren, Therese Takas, M. Abram, A. Leach, M. P. Griffin, T. Villafana   +17 more
semanticscholar   +1 more source

Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults.

New England Journal of Medicine, 2023
BACKGROUND Respiratory syncytial virus (RSV) can cause serious lower respiratory tract disease in older adults, but no licensed RSV vaccine currently exists.
A. Falsey, Kristi Williams, E. Gymnopoulou, S. Bart, J. Ervin, A. R. Bastian, J. Menten, E. de Paepe, Sjouke Vandenberghe, Eric K. H. Chan, J. Sadoff, M. Douoguih, Benoît Callendret, C. Comeaux, E. Heijnen   +14 more
semanticscholar   +1 more source